A new study has found that RTS,S malaria vaccine could enhance the production of protective antibodies upon subsequent parasite infection. The study was led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by "la Caixa". The results, published in BMC Medicine, identify the antigens (or protein fragments) that could be included in future, more effective multivalent vaccines.
Immunity to a pathogen can be acquired by natural exposure to the microorganism or through vaccination. The mechanisms underlying both types of immunity are not always the same, particularly in the case of parasites with complex life cycles, such as Plasmodium falciparum, that causes malaria. Over the last few years, ISGlobal researcher Carlota Dobaño and her team have been investigating the immune response induced by the RTS,S, the most advanced malaria vaccine that will be tested at large scale in sub-Saharan Africa this year.
Malaria
Malaria is caused by a parasite that enters blood through the bite of an infected mosquito. It is characterized by fever, vomiting, shivering, sweating and other symptoms.
In this study, the authors investigated how vaccination affects natural immunity to the parasite upon subsequent exposure. "To date, most studies had focused on evaluating vaccine-specific responses but not responses towards other parasite antigens," explains Gemma Moncunill, last author of the study. The RTS,S vaccine contains one single parasitic antigen: a fragment of the CSP protein.
Malaria - Protection Strategies
Malaria is a dangerous disease with lethal consequences that requires protective measures for prevention and control of malaria in endemic regions of the world.
They found three patterns of antibody responses to these antigens: those that decrease after vaccination, those that are unchanged, and those that increase. Many antibodies in the first group are considered markers of parasite exposure and were associated with a higher malaria risk. Those in the third group were associated with protection - they reduced by half the risk of developing the disease. These protective antibodies mostly recognised antigens expressed by parasite stages that circulate in the blood ant that infect red blood cells.
"We think that the partial efficacy of the vaccine allows low infection levels upon subsequent parasite exposure which in turn leads to the production of protective antibodies," explains Carlota Dobaño. "This effect would be observed especially in regions with low to moderate transmission levels," she adds.
Source: Eurekalert
Quiz on Malaria
Malaria is a common parasitic disease of the tropics, resulting in a million deaths every year. Early detection and adequate treatment at the right time can reduce deaths due to malaria. Test your knowledge on this condition by taking this quiz.
 Nanovectors Can Enhance The Administration Of Combined Antimalarial DrugsCombining different two drugs with different properties into nanovesicles surrounded by antibodies can hugely improve their delivery and efficiency. | Advertisement
|
Recommended Reading
Latest Tropical Disease News
